Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Schmit

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 8, 2000
Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populationsK Van Laethem, K Van Vaerenbergh, J C Schmit, et al.
AIDS Research and Human Retroviruses|April 25, 2000
Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapyK Van Vaerenbergh, K Van Laethem, E Van Wijngaerden, et al.
AIDS Research and Human Retroviruses|April 18, 2002
Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patientsK Van Vaerenbergh, T Harrer, J-C Schmit, et al.
Antiviral Therapy|June 22, 2001
Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-upA M Vandamme, F Houyez, D Bànhegyi, et al.
AIDS Research and Human Retroviruses|June 30, 2000
Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patientsK Van Laethem, J C Schmit, H Pelemans, et al.
The Journal of Antimicrobial Chemotherapy|March 6, 2015
Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in EuropeJ E Swartz, L Vandekerckhove, H Ammerlaan, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2000
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analoguesK Van Vaerenbergh, K Van Laethem, J Albert, et al.
Acta Dermatovenerologica Alpina, Pannonica, Et Adriatica|March 11, 2011
HIV-1 drug-resistance patterns among patients on failing treatment in a large number of European countriesD A M C van de Vijver, A M J Wensing, B Åsjö, et al.
Antiviral Therapy|January 18, 2005
Updated European recommendations for the clinical use of HIV drug resistance testingA M Vandamme, A Sönnerborg, M Ait-Khaled, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 2, 2015
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in EuropeL Marije Hofstra, Nicolas Sauvageot, Jan Albert, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 8, 2000
Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populationsK Van Laethem, K Van Vaerenbergh, J C Schmit, et al.
AIDS Research and Human Retroviruses|April 25, 2000
Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapyK Van Vaerenbergh, K Van Laethem, E Van Wijngaerden, et al.
AIDS Research and Human Retroviruses|April 18, 2002
Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patientsK Van Vaerenbergh, T Harrer, J-C Schmit, et al.
Antiviral Therapy|June 22, 2001
Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-upA M Vandamme, F Houyez, D Bànhegyi, et al.
AIDS Research and Human Retroviruses|June 30, 2000
Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patientsK Van Laethem, J C Schmit, H Pelemans, et al.
The Journal of Antimicrobial Chemotherapy|March 6, 2015
Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in EuropeJ E Swartz, L Vandekerckhove, H Ammerlaan, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2000
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analoguesK Van Vaerenbergh, K Van Laethem, J Albert, et al.
Acta Dermatovenerologica Alpina, Pannonica, Et Adriatica|March 11, 2011
HIV-1 drug-resistance patterns among patients on failing treatment in a large number of European countriesD A M C van de Vijver, A M J Wensing, B Åsjö, et al.
Antiviral Therapy|January 18, 2005
Updated European recommendations for the clinical use of HIV drug resistance testingA M Vandamme, A Sönnerborg, M Ait-Khaled, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 2, 2015
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in EuropeL Marije Hofstra, Nicolas Sauvageot, Jan Albert, et al.
Pageof 9